MedTrace Logo

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

NCT00729846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2016-04-20

Study results available
· View outcomes & findings →

Summary

To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degeneration.

Conditions

  • Age Related Macular Degeneration
  • Choroidal Neovascularization
  • Macular Edema

Interventions

DRUG

Bevacizumab

Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.

DEVICE

verteporfin photodynamic therapy reduced fluence

Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].

DEVICE

verteporfin photodynamic therapy standardfluence

Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • California Retina Consultants

    lead OTHER

Principal Investigators

  • Dante J Pieramici, MD · California Retina Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-08-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00729846 on ClinicalTrials.gov